Other

Sony Deutschland Gmbh

Charité – Universitätsmedizin Berlin

Charite Universitaetsmedizen-berlin

Andreas Meisel

Akio Yasuda

Tzenka Miteva

Dieter Neher

Christel Bonnas

Ulrich Dirnagl

Josef Priller

Gabriele Nelles

Donald Lupo

Wolfgang Knoll

Heinz-Georg Nothofer

Martin Grell

Christian Meisel

Ullrich Scherf

Konstantin Prass

Elke Halle

Hans Dieter Volk

Dieter Meher

The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammation, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS) of the nervous system.

Erythropoietin variants

In one aspect the present invention is concerned with a method of cell culture, comprising the steps of (i) obtaining a stem or progenitor cell sample, (ii) culturing the stem or progenitor cell sample in media and under closed conditions appropriate to cause proliferation or differentiation of the stem or progenitor cells, wherein the media comprises a vEPO protein variant, (iii) purifying the stem or progenitor cells ex vivo. The invention relates to a method of increasing the number and survival of stem and progenitor cells in vitro and in vivo using a vEPO protein variant. The invention also relates to improved differentiation of stem and progenitor cells in vitro and in vivo using a vEPO protein variant.

Method of cell culture and method of treatment comprising a vEPO protein variant

The invention refers to agents for the preventive therapy after acute stroke, in particular having the aim to prevent infections after stroke. The agents inventively employed in pharmaceutical preparations are anti-infective agents and/or immunomodulating agents, e.g. cytokines and/or inhibitors of the SNS.

Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident

The invention relates to aligned emissive polymer blended with at least one chromophore with rigid-rod-type or discotic asymmetric molecular structure; to film incorporating such polymer blends; to devices incorporating such polymers blends or films, and to uses thereof.

Aligned emissive polymer blend, film and device based thereon

The present invention relates to polyfluorenes end-capped with at least one charge-transporting moiety, and to films and devices based thereon.

End-capped polyfluorenes, films and devices based thereon

The invention relates to novel layers comprising polyimide and organic functional material such as hole transport material, electron transport material and/or emitter material having a glass transition temperature of higher than 80&deg; C. The layers can be prepared by mixing the functional material with a polyimide precursor material, forming a thin film out of the mixture and converting said mixture into doped polyimide. Said doped polyimide layers can be used for the manufacture of electronic and optoelectronic devices such as e.g. light emitting devices. Due to the content of functional material, they can act as hole transport, electron transport or emitter layer. Moreover, the layers can be processed to have aligning properties for liquid crystals, thus allowing the manufacture of devices emitting polarized light. Furthermore, after conversion to doped polyimide, the layers are resistant to solvent treatment allowing the preparation of multi-layers by successive coating and conversion cycles.

Polyimide layer comprising functional material, device employing the same and method of manufacturing same device

Growing community of inventors

Berlin, Germany

Andreas Meisel